Replies to post #141489 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

LE: Yes, it is at the top of our list of goals for 2016. In addition to the ovarian cancer study with Kevetrin and the ABSSSI Phase 3 with brilacidin, we also plan on starting a brilacidin trial for ulcerative proctitis in March. That represents another use of this product, as an anti-inflammatory. We are also presently in a Phase 2 trial for oral mucositis with brilacidin under an FDA fast track designation, and we would hope to get interim data for that in the upcoming months.

http://www.thelifesciencesreport.com/pub/na/a-small-cap-biotech-with-big-ideas-for-acute-infections-and-cancers-cellceutixs-leo-ehrlich-and-dr-daniel-jorgensen

Where was it stated that this was going to start up in March of 2016? I can't seem to find it.

[MinnieM]

From last 10-Q filed 2.8.16:

http://www.sec.gov/Archives/edgar/data/1355250/000147793216008473/ctix_10q.htm

Brilacidin -- Ulcerative Proctitis / Colitis and Hidradenitis Suppurativa

We have also identified inflammatory gastrointestinal disease (ulcerative proctitis) and inflammatory skin disease (hidradenitis suppurativa) as indications for treatment with Brilacidin or our other HDP mimics. The Company plans for a Phase 2 proof of concept trial for ulcerative proctitis to begin in March 2016.

It will be interesting to see if it actually starts this month or next. I view most of these dates as moving targets.






In Reply to 'bejamin'
Where was it stated that this was going to start up in March of 2016? I can't seem to find it.


Know What You Own